Open Access Open Access  Restricted Access Subscription Access

Exploring ProTides: Molecular Mechanism and Progress in Clinical Development

Sudarshan Rajput, Vaibhav Patil, Chetan Chaudhari, Vansh Patel, Jaykumar Rajput, Sanjaykumar Bari, Vishal Bagul

Abstract


ProTide technology, a phosphoramidate-based prodrug strategy, has significantly advanced drug design by enhancing the delivery and activation of nucleoside analogues. By chemically masking the phosphate group, ProTides improve cellular uptake, bypass rate-limiting phosphorylation steps, and enable efficient intracellular release of active monophosphates. This review highlights the structural modifications, mechanistic pathways, and clinical translation of ProTides in antiviral and anticancer therapies. Key FDA-approved drugs such as sofosbuvir, remdesivir, and tenofovir alafenamide demonstrate the success of this approach in overcoming drug resistance, improving bioavailability, and reducing toxicity. Mechanistic insights reveal how esterases and phosphoramidases mediate selective cleavage, releasing the active drug within target cells. Additionally, synthetic strategies for ProTides, including Methods A and B, offer scalable solutions for clinical development. The integration of ProTide chemistry into modern drug discovery exemplifies its transformative role in pharmacology and its potential to address current challenges in therapeutic efficacy and safety.


Full Text:

PDF

References


Albert, Adrien. "Chemical aspects of selective toxicity." Nature 182.4633 (1958): 421-423. https://doi.org/10.1038/182421a0

Sharifi, Majid, et al. "Enzyme immobilization onto the nanomaterials: Application in enzyme stability and prodrug-activated cancer therapy." International Journal of Biological Macromolecules 143 (2020): 665-676. https://doi.org/10.1016/j.ijbiomac.2019.12.064

De Clercq, Erik, and Guangdi Li. "Approved antiviral drugs over the past 50 years." Clinical microbiology reviews 29.3 (2016): 695-747. https://doi.org/10.1128/cmr.00102-15

Slusarczyk, Magdalena, Michaela Serpi, and Fabrizio Pertusati. "Phosphoramidates and phosphonamidates (ProTides) with antiviral activity." Antiviral Chemistry and Chemotherapy 26 (2018): 2040206618775243. https://doi.org/10.1177/2040206618775243

Elsharif, N., and O. Dakhil. "Review article about modified nucleosides (Pro-Tide) as potential anti-HCV Therapeutics." Libyan Journal of Science &Technology 5.1 (2017).

Serpi, Michaela, and Fabrizio Pertusati. "An overview of ProTide technology and its implications to drug discovery." Expert Opinion on Drug Discovery 16.10 (2021): 1149-1161. https://doi.org/10.1080/17460441.2021.1922385

Siccardi, Dario, et al. "Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidatetriester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers." The Journal of pharmacology and experimental therapeutics 307.3 (2003): 1112-1119. ttps://doi.org/10.1124/jpet.103.056135

McGuigan, C., et al. "Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency." Antiviral Chemistry and Chemotherapy 9.2 (1998): 109-115. https://doi.org/10.1177/095632029800900202

Murakami, Eisuke, et al. "Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977." Journal of biological chemistry 285.45 (2010): 34337-34347. DOI 10.1074/jbc.M110.161802

Procházková, Eliška, et al. "Reactive cyclic intermediates in the ProTide prodrugs activation: trapping the elusive pentavalent phosphorane." Organic & biomolecular chemistry 17.2 (2019): 315-320. https://doi.org/10.1039/C8OB02870B


Refbacks

  • There are currently no refbacks.